OncoMatch/Clinical Trials/NCT04677413
Ultra-fractionated Radiotherapy for Rectal Cancer
Is NCT04677413 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for rectal cancer.
The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
wbc ≥ 3,000/ml; anc wbc ≥ 1,000/ml; plt ≥ 75,000/ml
Kidney function
creatinine not above uln, or creatinine clearance >50 ml/min/1.73 m^2 for participants with creatinine levels above institutional normal
Liver function
t bili ≤ 1.5 x uln; ast/alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify